<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02637947</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-021</org_study_id>
    <nct_id>NCT02637947</nct_id>
  </id_info>
  <brief_title>Comparison of VT Ablation Outcomes Using Remote MAGNETIC Navigation Versus Manual Approach in a Low LVEF Population</brief_title>
  <acronym>MAGNETIC-VT</acronym>
  <official_title>A Prospective, Multi-center, Post Market Randomized Controlled Trial Comparing VT Ablation Outcomes Using Remote MAGNETIC Navigation Guided Substrate Mapping and Ablation Versus Manual Approach in a Low LVEF Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stereotaxis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stereotaxis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study purpose is to demonstrate that ventricular tachycardia (VT) ablation using the
      Niobeâ„¢ ES system results in superior outcomes compared to a manual approach in subjects with
      ischemic scar VT in a low ejection fraction population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, single-blind, prospective, multi-center post market evaluation.
      Subjects will be screened for study eligibility and asked to complete written informed
      consent prior to any study specific testing assessments. After completing written informed
      consent, a total of 386 subjects will be randomized on a 1:1 basis to receive VT ablation
      treatment using either the Niobe ES or standard manual catheter ablation treatment using
      commercially available products. This will be the largest randomized VT study comparing
      outcomes from RMN to manually guided catheter ablation procedures. Subjects will be
      randomized according to a computer-generated randomization scheme. Randomization will be
      blocked at the study site level and subjects will be blinded to group assignment. Since
      quality of life measurements will be collected during follow-up, this study is single-blinded
      in order to mitigate patient bias. Clinical evaluations will not be masked to the treating
      physician.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>freedom from any VT in the overall cohort</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>acute success of procedure</measure>
    <time_frame>at end of procedure (immediate)</time_frame>
    <description>non-inducibility of clinical VT and/or other monomorphic VT using typical stimulation protocol for induction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>freedom from VT in large scar subpopulation</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major adverse events</measure>
    <time_frame>48 hours post-procedure</time_frame>
    <description>death, cardiac tamponade, stroke, bleeding requiring surgical intervention, progressive heart failure related to VT/VF recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality rate</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Total number of appropriate ICD defibrillator shocks</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total number of ICD applications of anti-tachycardia pacing</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total procedure time (skin to skin)</measure>
    <time_frame>through end of acute procedure, an average of 3 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total fluoroscopy time</measure>
    <time_frame>through end of acute procedure, an average of 3 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total fluoroscopy dose</measure>
    <time_frame>through end of acute procedure, an average of 3 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total mapping time</measure>
    <time_frame>through end of acute procedure, an average of 3 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total ablation time</measure>
    <time_frame>through end of acute procedure, an average of 3 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total mapping points prior to ablation</measure>
    <time_frame>through end of acute procedure, an average of 3 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total ablation energy delivery</measure>
    <time_frame>through end of acute procedure, an average of 3 hours</time_frame>
    <description>Watts X seconds / Total scar surface area</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of stay in hospital</measure>
    <time_frame>1 week</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient quality of life (SF-12)</measure>
    <time_frame>12 months</time_frame>
    <description>Medical Outcomes Study 12-item Short-Form Health Survey</description>
  </other_outcome>
  <other_outcome>
    <measure>Health Outcome Measure (EQ-5D-5L)</measure>
    <time_frame>12 months</time_frame>
    <description>standardized measure of health status</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">386</enrollment>
  <condition>Tachycardia, Ventricular</condition>
  <arm_group>
    <arm_group_label>Magnetic navigation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Catheter ablation using magnetic navigation for ventricular tachycardia via remote magnetic navigation of a NaviStar RMT ThermoCool catheter, or other magnetically compatible catheter, via Stereotaxis's Niobe ES system.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Manual navigation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Catheter ablation using manual navigation for ventricular tachycardia via a manually navigated Thermocool catheter, or equivalent catheter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>catheter ablation using magnetic navigation</intervention_name>
    <description>elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of Stereotaxis's Niobe ES System with the NaviStar RMT ThermoCool catheter or other magnetically compatible catheters.</description>
    <arm_group_label>Magnetic navigation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>catheter ablation using manual navigation</intervention_name>
    <description>elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of the NaviStar ThermoCool catheter or other manually navigated catheters.</description>
    <arm_group_label>Manual navigation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subject has had an ICD previously implanted

          -  subject has drug-refractory monomorphic VT

          -  subject is a candidate for ischemic VT RF ablation

          -  subject has had a myocardial infarction

          -  subject has a LVEF less than or equal to 35%

        Exclusion Criteria:

          -  subject has non-ischemic VT

          -  subject has a history of stroke within 1 month prior to enrollment

          -  subject has had an acute myocardial infarction within 30 days prior to enrollment

          -  subject has unstable angina

          -  subject has undergone cardiac surgery within 60 days prior to enrollment

          -  subject is pregnant or nursing

          -  subject has a limited life expectancy of 1 year or less (Subjects requiring LVAD/IABP
             intraprocedural support may be enrolled as long as life expectancy is at least 1 year
             following the ablation procedure.)

          -  subject is unable or unwilling to cooperate with study procedures

          -  subject has a known presence of intracardiac thrombi as determined by echocardiography

          -  subject has a major contraindication to anticoagulation therapy or coagulation
             disorder

          -  subject has had a previous pericarditis or cardiac tumor

          -  subject has had previous thoracic radiation therapy

          -  any other reason the investigator considers the subject ineligible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Natale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Cardiac Arrhythmia Research Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ken Lock</last_name>
    <phone>13146786123</phone>
    <email>ken.lock@stereotaxis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Jordan</last_name>
      <phone>706-721-0193</phone>
      <email>jujordan@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Berman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shahram Sarrafi</last_name>
      <phone>773-702-0535</phone>
      <email>ssarrafi1@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Roderick Tung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Christ Medical Center</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Nellett</last_name>
      <phone>708-684-4522</phone>
      <email>michelle.nellett@advocatehealth.com</email>
    </contact>
    <investigator>
      <last_name>William Spear, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margana Morgan, B.S.</last_name>
      <phone>913-945-6443</phone>
      <email>mmorgan@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Dhanunjaya Lakkireddy, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace A Lee</last_name>
      <phone>646-962-8493</phone>
      <email>grl2008@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Jim W Cheung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Research Foundation</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deb Cardinal</last_name>
      <phone>512-458-9410</phone>
      <email>dscardinal@austinheartbeat.com</email>
    </contact>
    <investigator>
      <last_name>Andrea Natale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intermountain Heart Institute</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darija Runjaic-Ward</last_name>
      <phone>801-507-4722</phone>
      <email>Darija.RunjaicWard@imail.org</email>
    </contact>
    <investigator>
      <last_name>J. Peter Weiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia King</last_name>
      <phone>(02) 8890 4719</phone>
      <email>mailto:patricia.king@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Pramesh Kovoor, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <state>West Flanders</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrien Derycker</last_name>
      <phone>32 50 45 38 96</phone>
      <email>katrien.derycker@azsintjan.be</email>
    </contact>
    <investigator>
      <last_name>Rene Tavernier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marleen Bogaert</last_name>
      <phone>+32 3 280 32 09</phone>
      <email>marleen.bogaert@zna.be</email>
    </contact>
    <investigator>
      <last_name>Bruno Schwagten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Praha</city>
        <zip>15030</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jitka Hofmanova</last_name>
      <phone>+420 257 272 376</phone>
      <email>Jitka.Hofmanova@homolka.cz</email>
    </contact>
    <investigator>
      <last_name>Petr Neuzil, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aslaug Karlsdottir</last_name>
      <phone>4535457059</phone>
      <email>aslaug.thora.karlsdottir@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Xu Chen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu De Nancy - HÃ´pitaux De Brabois</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VÃ©ronique Midenet</last_name>
      <phone>+33 383153881</phone>
      <email>v.midenet@chru-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Christian De Chillou, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis (OLVG)</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rukiye Akpinar-Turan</last_name>
      <email>r.turan@olvg.nl</email>
    </contact>
    <investigator>
      <last_name>Muchtiar Khan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petter Janse</last_name>
      <phone>+31 10 7035018</phone>
      <email>p.janse@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Tamas Szili-Torok, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2015</study_first_submitted>
  <study_first_submitted_qc>December 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2015</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

